Market Exclusive

Analyst Activity – Cowen Reiterates Buy on Intra-Cellular Therapies (NASDAQ:ITCI)

Analyst Ratings For Intra-Cellular Therapies (NASDAQ:ITCI)

Today, Cowen reiterated its Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) with a price target of $28.00.

Some recent analyst ratings include

Recent Insider Trading Activity For Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI) has insider ownership of 19.80% and institutional ownership of 76.93%.

Recent Trading Activity for Intra-Cellular Therapies (NASDAQ:ITCI)
Shares of Intra-Cellular Therapies closed the previous trading session at 18.95 up +0.91 5.04% with shares trading hands.

Exit mobile version